

# Prior Authorization Request Form for Rebetol (ribavirin oral capsule and solution), Copegus (ribavirin oral tablet), and Ribasphere (ribavirin oral capsule)

## Member Information

Patient Name \_\_\_\_\_  
 Cardholder ID \_\_\_\_\_  
 Date of Birth \_\_\_\_\_  
 Address \_\_\_\_\_  
 City, State Zip \_\_\_\_\_  
 Phone Number \_\_\_\_\_

## Provider Information

Provider Name \_\_\_\_\_  
 DEA Number \_\_\_\_\_  
 Address \_\_\_\_\_  
 City, State and Zip \_\_\_\_\_  
 Phone Number \_\_\_\_\_  
 FAX Number \_\_\_\_\_

## Pharmacy Information

Pharmacy Name \_\_\_\_\_ Address \_\_\_\_\_ Phone \_\_\_\_\_

### Criteria for Approval:

1. Ribavirin drug requested? *Check one:* Rebetol caps  Copegus  Ribasphere  Rebetol Solution
2. Does the patient have a diagnosis of chronic hepatitis C with signs present and demonstrated on liver biopsy?  

	Yes <input type="checkbox"/>	No <input type="checkbox"/>
--	------------------------------	-----------------------------
3. Does the patient have a history of heart disease?  

	Yes <input type="checkbox"/>	No <input type="checkbox"/>
--	------------------------------	-----------------------------
4. Does the patient have: *Check all that apply:*  

Hemoglobin > 8.5 gm/dL <input type="checkbox"/>	Creatinine clearance $\geq$ 50 ml/min/1.73m <sup>2</sup> <input type="checkbox"/>
---	---
5. Does the patient have: *Check all that apply:*  

Detectable levels of hepatitis C virus (HCV) RNA in the serum <input type="checkbox"/>	
Persistently elevated serum alanine aminotransferase (ALT) levels > 2 times the upper limit <input type="checkbox"/>	
6. Is the patient: *Check one:*  

Female and pregnant or planning to become pregnant <input type="checkbox"/>	
Male with a partner that is planning to become pregnant <input type="checkbox"/>	
7. Has or will the patient be instructed to practice effective contraceptives during therapy and six months after therapy with ribavirin therapy?  

	Yes <input type="checkbox"/>	No <input type="checkbox"/>
--	------------------------------	-----------------------------
8. Has the patient received interferon therapy within the previous year?  

	Yes <input type="checkbox"/>	No <input type="checkbox"/>
--	------------------------------	-----------------------------
9. Did the patient respond to the previous interferon therapy?  

	Yes <input type="checkbox"/>	No <input type="checkbox"/>
--	------------------------------	-----------------------------
10. Will the patient be on Intron A or Pegasys concurrently with ribavirin?  

	Yes <input type="checkbox"/>	No <input type="checkbox"/>
--	------------------------------	-----------------------------
11. Will the patient be monitored for depression during therapy?  

	Yes <input type="checkbox"/>	No <input type="checkbox"/>
--	------------------------------	-----------------------------
12. Will the hemoglobin levels be monitored during therapy?  

	Yes <input type="checkbox"/>	No <input type="checkbox"/>
--	------------------------------	-----------------------------
13. Is the patient being treated for relapse after monotherapy with an interferon product?  

	Yes <input type="checkbox"/>	No <input type="checkbox"/>
--	------------------------------	-----------------------------
14. If the patient has relapsed or did not respond to previous interferon therapy, will the patient be restarted on a higher dose regimen as labeling recommends?  

	Yes <input type="checkbox"/>	No <input type="checkbox"/>
--	------------------------------	-----------------------------

Provider Signature \_\_\_\_\_ Date \_\_\_\_\_

**Fax completed forms to (866) 284-4509.**

### For Office Use Only

Date/Time Received \_\_\_\_\_  
 Reference Number \_\_\_\_\_  
 Approved / Denied (Circle One) by \_\_\_\_\_ Date \_\_\_\_\_  
 Date/Time Returned to Provider \_\_\_\_\_

If you have any questions regarding this form, contact the Prior Authorization Department Toll Free at (866) 284-4492 or FAX Toll Free at (866) 284-4509.

FOX Rx Care Utilization Management  
 3375-I Capital Circle NE  
 Tallahassee, FL 32308

IMPORTANT NOTICE: This facsimile is intended to be delivered to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure and applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by other than the named addressee, except by express authority of the sender to the named addressee..

